Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Anthropic IPO Marketing Expected to Start in Mid-October 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
CHESTERBROOK, Pa., Feb. 28, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 7, 2018 at 8:00 am EST to review financial results as of and for the quarter and year ended December 31, 2017 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 7843918).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 7843918). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product OLINVO™ (oliceridine) Injection for the management of moderate-to-severe acute pain. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
SVP, scientific affairs and investor relations officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
